3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
57
Carcinoma, Renal Cell
18
Urinary Bladder Neoplasms
13
Neoplasm Metastasis
8
Sarcoma
7
Ovarian Neoplasms
6
Melanoma
6
Glioma
6
Breast Neoplasms
6
Wilms Tumor
5
Uterine Cervical Neoplasms
5
Pancreatic Neoplasms
5
Neuroectodermal Tumors, Primitive, Peripheral
5
Neuroblastoma
5
Lymphoma, Non-Hodgkin
5
Kidney Neoplasms
5
Carcinoma, Transitional Cell
5
Rhabdoid Tumor
4
Neoplasms
4
Medulloblastoma
4
Lung Neoplasms
4
Histiocytosis, Langerhans-Cell
4
Hepatoblastoma
4
Ependymoma
4
Colorectal Neoplasms
4
Clear-cell metastatic renal cell carcinoma
4
Central Nervous System Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Urethral Neoplasms
3
Ureteral Neoplasms
3
Interventions
enzalutamide
10
Abiraterone Acetate
6
rucaparib
2
Prednisone
2
Docetaxel
2
tildrakizumab
1
sabizabulin
1
pembrolizumab
1
fluzoparib
1
apatinib
1
abiraterone
1
Pluvicto
1
N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide
1
Blood Specimen Collection
1
Biopsy
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration Resistant Prostate Cancer
×
Biopsy
×
Genitourinary
×
Clear all
NCT02424448
2016-07-26
BIOMETHS
The Christie NHS Foundation Trust
Completed
6 enrolled